[0:00–0:28]
On-Screen Title: Breakthrough remote monitoring device may detect heart failure events earlier
Narrator: Standard remote monitoring for heart failure has been shown to reduce rates of hospitalization and improve quality of life for patients. But the current standard of care monitors blood pressure, which can have a lag time of up to 10 days for accurate indications, therefore impeding the efficacy of monitoring and potentially resulting in a significant deterioration of health.
On-Screen Title: The current standard of care monitors blood pressure and weight, has a lag time of up to 10 days, can result in a significant health situation
[0:29–0:42]
Narrator: Dr. Nir Uriel and his team at NewYork-Presbyterian and Columbia have been studying a novel remote heart monitoring device which uses a different mechanism to detect heart failure events even earlier. They just finished an early feasibility study, which yielded promising results.
[0:43–1:03]
Narrator: The FIRE1 device takes a different approach to remote monitoring. Through a stent, it measures changes in the size of the inferior vena cava to relay information about the blood volume of a patient. By measuring volume as opposed to pressure, it can directly detect fluid buildup and therefore predict and prevent heart failure events at an earlier stage.
[1:04–1:32]
Narrator: The device works through a sensor implanted using fluoroscopic guidance and deployed within the inferior vena cava between the renal and hepatic veins to track changes in inferior vena cava size. All 15 patients in the study had successful implantations, reaching the primary safety endpoint at 30 days, and both the primary safety and effectiveness endpoints at three months. Sensor-derived inferior vena cava area measurements strongly correlated with CT-measured values and were extremely accurate.
On-Screen Title: Results: Successful implantations in all 15 patients, reached primary safety endpoint at 30 days, met primary safety and effectiveness endpoints at 3 months
[1:33–1:52]
Narrator: The success of this study is now paving the way for a larger randomized clinical trial. Not only is this improving prediction accuracy, but it’s expanding the access and feasibility of remote monitoring for certain groups of patients with heart failure who may not have been candidates before.
[END]
